Skip to search formSkip to main contentSkip to account menu

simoctocog alfa 1 UNT Injection [Nuwiq]

Known as: Nuwiq 1 UNT Injection, Simoctocog Alfa 2000 [iU] in 2.5 mL INTRAVENOUS POWDER, FOR SOLUTION [NUWIQ], Simoctocog Alfa 1000 [iU] in 2.5 mL INTRAVENOUS POWDER, FOR SOLUTION [NUWIQ] 
National Institutes of Health

Related topics

Related topics

2 relations
InjectionNuwiq

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Haemophilia A Prophylaxis with FVIII in Real-life: Snapshot Analysis on the Observational Study “Prevention of Bleeding in Haemophilia A by Prophylactic Treatment with Octanate®, Wilate® or Nuwiq…
2019
2019
Personalized prophylaxis with simoctocog-alfa(human-cl rhFVIII):A real-life experience on children and moderate haemophilia A patients
Review
2018
Review
2018
Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq®, Octanate® or Wilate® — the…
Introduction/Objective: The development of FVIII inhibitors remains the greatest challenge to the treatment of previously… 
2018
2018
Immune Tolerance Induction with Simoctocog Alfa (Nuwiq®) in Six Patients with Severe Haemophilia a and FVIII Inhibitors
Introduction and Objective: Inhibitors to coagulation factor VIII (FVIII) are the most serious complication of haemophilia A… 
Review
2015
Review
2015
A new recombinant factor VIII: from genetics to clinical use
Dear editor The December 2014 issue of Drug Design, Development and Therapy included a review article by Santagostino entitled… 
2015
2015
Pharmacokinetic Properties of Different rFVIII Products in Rabbits, Rats and FVIII Ko Mice
Introduction: Current state of the art treatment of severe Hemophilia A is prophylactic or on-demand replacement of the deficient… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)